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ABSTRACT
Background: Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute liver decompensation 
with extrahepatic organ failure in patients with pre-existing liver disease causing high short-term mortality. A 
good knowledge about characteristics and diagnostic of ACLF will help us to give proper treatment. The aim 
of this study is to know WKHSUR¿OHDQGFKDUDFWHULVWLFVRI$&/)SDWLHQW
Method: 5HWURVSHFWLYHVWXG\ZDVFRQGXFWHGWR¿QGSDWLHQWZLWK$&/)EHWZHHQ-DQXDU\-DQXDU\
at Fatmawati General Hospital.
Results: Ten patients were diagnosed with ACLF. Six patients admitted with a chief complaint: unconscious, 
2 of them had hematemesis in the course-of-treatment. Three patients were admitted with abdominal pain, and 1 
patient with hematemesis-melena. Seven patients had hepatitis-B infection. Aspartate-transaminase to platelet-
ratio index (APRI) values varied (median 8.1;minimum 2.81-maximum 34.67). Hepatic encephalopathy, ascites, 
DQGDFXWHUHQDOIDLOXUHZHUHIRXQGLQRISDWLHQWV-DXQGLFHFDQEHIRXQGLQDOOSDWLHQWVZLWKPHDQYDOXHV
RIELOLUXELQOHYHOVLQSDWLHQWVXQGHUJRLQJWHVWIRUELOLUXELQOHYHOZHUHPJG/&RDJXODWLRQGLVRUGHUV
ZHUHIRXQGLQRISDWLHQWVXQGHUJRLQJKDHPRVWDVLVWHVW)RXUSDWLHQWVZHUHGLDJQRVHGZLWKJUDGH$&/)
All ACLF patients eventually died during treatment, including third-degree patients who all died within 7 days. 
Only 2 patients survived more than 7 days, and 4 patients died within 3 days of treatment. 
Conclusion: mortality rates of ACLF were very high, and are often found in patients with advanced liver 
disease characterized by high APRI values. The prognosis is related to the number of organ failures. Central 
nervous system, kidneys and liver are the organs that are often impaired. Because the current treatment method is 
still limited, further research is needed, especially on biomarkers for better prevention, diagnosis and treatment.
Keywords: acute on chronic liver failure, mortality, case-series
ABSTRAK
Latar belakang: Acute-on-chronic liver failure (ACLF) merupakan sindrom yang ditandai dengan 
dekompensasi hati akut dan kegagalan organ ekstrahepatik pada pasien dengan riwayat penyakit hati yang 
sering menyebabkan kematian jangka pendek. Pengetahuan yang baik tentang karakteristik dan diagnostik 
ACLF akan membantu kami memberikan perawatan yang tepat. Tujuan penelitian ini adalah untuk mengetahui 
SUR¿OGDQNDUDNWHULVWLNSDVLHQ$&/)
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Metode: 6WXGLUHWURVSHNWLIGLODNXNDQXQWXNPHQHPXNDQSDVLHQGHQJDQ$&/)DQWDUD-DQXDUL-DQXDUL
GL5XPDK6DNLW8PXP)DWPDZDWL
Hasil: 'LGDSDWNDQSDVLHQ$&/)HQDPSDVLHQGLDQWDUDQ\DGDWDQJGHQJDQNHOXKDQXWDPDWLGDNVDGDU7LJD
pasien masuk rumah sakit dengan keluhan utama sakit perut, dan 1 pasien datang dengan hematemesis-melena. 
Tujuh pasien memiliki riwayat infeksi hepatitis B. Nilai aspartate-transaminase to platelet-ratio index (APRI) 
bervariasi (median 8.1; minimum 2,81-maksimum 34,67). Ensefalopati hepatikum, asites, dan gagal ginjal akut 
GLWHPXNDQSDGDSDVLHQ-DXQGLFHGDSDWGLWHPXNDQSDGDVHPXDSDVLHQGHQJDQUHUDWDQLODLNDGDUELOLUXELQ
SDGDSDVLHQ\DQJGLODNXNDQSHPHULNVDDQVHEHVDUPJG/*DQJJXDQNRDJXODVLGLWHPXNDQSDGD
SDVLHQ\DQJPHQMDODQLSHPHULNVDDQKHPRVWDVLV(PSDWSDVLHQWHUGLDJQRVLV$&/)JUDGH6HPXDSDVLHQ
ACLF pada akhirnya meninggal dalam perawatan termasuk pasien derajat 3 yang semua meninggal dalam 
waktu 7 hari. Hanya 2 pasien yang bertahan lebih dari 7 hari, dan 4 pasien meninggal dalam 3 hari perawatan. 
Simpulan: Angka mortalitas ACLF sangat tinggi, dan sering dijumpai pada pasien dengan penyakit hati 
lanjut yang ditandai dengan tingginya nilai APRI. Prognosis terkait dengan jumlah kegagalan organ yang 
timbul. Sistem saraf pusat, ginjal dan hati adalah organ-organ yang sering mengalami gangguan. Oleh karena 
metode pengobatan saat ini masih terbatas maka diperlukan penelitian lebih lanjut, terutama pada biomarker 
untuk pencegahan, diagnosis dan perawatan yang lebih baik.
Kata kunci: acute-on-chronic liver failure (ACLF), angka kematian, serial kasus
INTRODUCTION
Acute on chronic liver failure (ACLF) is a syndrome 
marked by liver decompensation accompanied by multi 
organ failure which has very high mortality rate.1 Signs 
of acute liver decompensation observed in ACLF are 
jaundice and coagulation disorders. In addition to acute 
liver decompensation, ACLF can also be accompanied 
by one or more extrahepatic organ failure with very 
high 28 days to 3 months mortality. ACLF cases are 
usually started with a trigger in the form of bacterial 
infection, extrahepatic sepsis, alcoholism, and viral 
infection including relapse or acute exacerbation of 
viral hepatitis. But, in 40-50% cases, the trigger of 
$&/) LV GLI¿FXOW WR LGHQWLI\([DJJHUDWHG V\VWHPLF
LQÀDPPDWLRQUHVSRQVHLVSUHGLFWHGWRSOD\DQLPSRUWDQW
role in the emergence of ACLF.1 
)RUPRUHWKDQWZRGHFDGHVWKHXQLIRUPGH¿QLWLRQ
of ACLF has not been agreed causing the reporting 
of prevalence, mortality rate, and prognosis to vary. 
High mortality rate in patients with ACLF is usually 
related to the number of organ dysfunction. ACLF has 
a mortality rate 15 times higher compared to acute 
decompensated condition without ACLF. CANONIC 
study showed that mortality in 28 days in overall ACLF 
degree was 33%. Meanwhile, the 28 days mortality 
rate in patients with grade 1, 2, and 3 ACLF was 
22%, 32%, and 73%, respectively. In 3-7 days after 
$&/)GLDJQRVLV KDV EHHQ FRQ¿UPHG SDWLHQWPLJKW
experience deterioration or even death. Therefore, it 
is very important to stratify patient according to the 
prognosis, evaluate treatment response, determine 
emergency condition for transplantation, treat patient 
in intensive care unit and decide whether the procedure 
WREHSHUIRUPHGZLOOEHEHQH¿FLDORUQRW1,2 
This preliminary study is performed to know the 
SUR¿OHFKDUDFWHULVWLFVDQGFOLQLFDORXWFRPHVRI$&/)
patients in Fatmawati General Hospital in order to 
provide an illustration and advanced management in 
the future. 
METHOD
This study used retrospective method through 
PHGLFDO UHFRUG UHYLHZ WR¿QG DOO SDWLHQWVZLWK WKH
diagnosis of ACLF in Fatmawati General Hospital 
between January 2017 and January 2018. ACLF 
diagnosis criteria being used was the European 
Association for the Study of the Liver (EASL) criteria. 
$&/) LV GH¿QHG DV DQ DFXWH GHFRPSHQVDWLRQ IURP
cirrhosis with multi organ failure and high short-term 
mortality (28 days mortality rate > 15%).1 Condition 
and number of organ failure evaluated with chronic 
liver failure-sequential organ failure assessment (CLIF-
SOFA) is associated with 28 days and 90 days mortality 
UDWH6HYHULW\RI$&/)LVFODVVL¿HGEDVHGRQWKHQXPEHU
of failed organ which is grade 1, grade 2, grade 3 and 
the mortality rate is correlated with severity of ACLF. 
ACLF severity degree is as follows: (1) Not ACLF with 
28 days mortality of < 5%: (a) no organ failure, (b) 
one organ failure in patient with creatinine serum of < 
1.5 mg/dL and no hepatic encephalopathy, (c) cerebral 
failure in patient with creatinine serum of < 1.5 mg/
dL; (2) grade I ACLF with 28 days mortality of 22%: 
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(a) kidney failure, (b) liver, coagulation, circulation or 
pulmonary failure which is associated with creatinine 
serum of 1.5-1.9 mg/dL and grade 1 or grade 2 hepatic 
encephalopathy, (c) brain failure with creatine serum of 
1.5-1.9 mg/dL; (3) grade 2 ACLF with 28 days mortality 
of 32%: 2 organ failure; (4) grade 3 ACLF with 28 days 
mortality of 77%: 3 organs failure or more.
Data on patients’ basic characteristics, chief 
complaint, physical examination, laboratory, and 
mortality were obtained from hospital medical records. 
Descriptive analysis was performed according to the 
collected data. 
RESULTS
We obtained ten inpatient patients in Fatmawati 
General Hospital between January 2017 and January 
2018 according to the EASL diagnosis criteria for 
ACLF. From those 10 patients, 6 patients were admitted 
to the hospital with the chief complaint of decrease 
consciousness, 3 patients were admitted with the chief 
complaint of abdominal pain, and 1 patient came with 
the chief complaint of hematemesis-melena. Two 
patients came without hematemesis complaint, but 
experienced hematemesis during hospitalization.
From the evaluation of aetiological factors and 
patients’ background, it was found that from a total of 
10 patients, 7 patients were infected with hepatitis-B, 2 
patients were infected with hepatitis C, and one patient 
was not infected by either hepatitis B or C.
Degree of severity and fibrosis status in these 
patients was evaluated using APRI score. Aspartate-
transaminase to platelet-ratio index (APRI) score in 
patients diagnosed with ACLF in Fatmawati General 
Hospital varied with a median score of 8.1; minimum 
2.81-maksimum 34.67. 
During the assessment of organ failure and liver 
decompensation in these patients, it was found that 90% 
patients who were admitted to the hospital experienced 
hepatic encephalopathy, ascites, and acute kidney 
failure during the hospitalization. Jaundice as a sign of 
acute liver decompensation can be found in all patients 
whose mean total bilirubin was 20.62 mg/dL. In addition 
to jaundice, coagulation disorder was found in 60% 
patients who underwent haemostasis examination. 
$&/)FODVVL¿FDWLRQDFFRUGLQJWRWKH&/,)62)$
criteria in these 10 patients found that grade 3 ACLF was 
found in 4 patients, while the rest fell into grade 2 ACLF 
criteria. All patients who were diagnosed with ACLF 
passed away. From all patients who passed away, only 
two patients were able to survive for more than seven 
days, while four patients passed away within three days 
of hospitalization. All grade three ACLF patients passed 
away within seven days of hospitalization.
DISCUSSION
ACLF is a liver decompensated disease with high 
PRUWDOLW\UDWHZKLFKWKHGLI¿FXOW\WRGLDJQRVHRIWHQ
causes delay in its management. Epidemiology data 
on ACLF is still rare; several new studies stated that 
in the United States, more than 700,000 patients who 
were hospitalized in a year has a diagnosis of liver 
cirrhosis and apparently 5% of them can be categorized 
Table 1. Basic and clinical characteristics of patients with acute on chronic liver failure (ACLF)
No Sex Age (years) Chief complaint
Hepatic 
encephalopathy
Shock on 
vasopressor Ascites Jaundice Viral hepatitis
Bacterial 
infection
1 F 36 Abdominal pain No Yes Yes Yes B Yes
2 M 67 Abdominal pain Yes No Yes Yes Non B/C No
3 M 39 Abdominal pain Yes No Yes Yes B Yes
4 M 47 Hematemesis melena Yes No Yes Yes B Yes
5 M 55 Unconscious Yes Yes Yes Yes B No
6 M 48 Unconscious Yes Yes Yes Yes C Yes
7 M 47 Unconscious Yes Yes No Yes B Yes
8 F 55 Unconscious Yes Yes Yes Yes B Yes
9 M 56 Unconscious Yes Yes Yes Yes B Yes
10 M 41 Unconscious Yes No Yes Yes C Yes
F= female, M=male
Table 2. Laboratory characteristics, severity of acute on chronic liver failure (ACLF) and time to death
No Thrombocyte AST ALT APRI Urea Creatinine Total bilirubin
Prothrombin 
Time ACLF
Length of 
hospitalization Comments
1 84 289 104 10.12 214 5.4 39.6 - 3 2 Passed away
2 189 1172 382 18.24 96 1.8 18.4 18.8(13.6) 2 6 Passed away
3 149 1201 818 23.71 28 1.7 34.1 - 2 1 Passed away
4 165 1945 1192 34.67 297 13.2 11.2 21.8(13.6) 2 4 Passed away
5 73 132 85 5.32 47 1.7 5.5 20.5(13.6) 2 10 Passed away
6 147 272 114 5.44 137 2 - - 3 1 Passed away
7 206 197 120 2.81 73 2 18 - 3 4 Passed away
8 399 396 129 2.92 214 2.1 18.8 21.1(13.6) 2 3 Passed away
9 70 233 155 9.79 60 1.1 11 - 2 8 Passed away
10 106 231 113 6.41 257 6 29 20.5(14.4) 3 4 Passed away
AST: asparte aminotransferase, ALT: alanine aminotransferase, APRI: AST to platelet ratio index
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into ACLF. A study in China conducted by Qin et al, 
stated that ACLF is more often to be observed in male 
patient and the incidence in 10-year period was 2.53 
IURPSRSXODWLRQ'XHWRWKHGLI¿FXOW\LQWKH
diagnosis and delay in the management, patient with 
ACLF usually has a longer hospitalization period and 
is associated with high mortality rate in ACLF.4,5 
A study by Qin et al in China in the year 2005-
2014 on the aetiology and predisposing factors of 
ACLF found that the most frequent aetiology was 
chronic HBV infection with 91% (1760 cases). 
Autoimmune (58.3%), alcoholism (53 cases; 2.74%), 
and chronic hepatitis C (23 cases; 1.19%) were 
among other aetiologies observed in ACLF patients.6 
Bacterial infection and gastrointestinal bleeding are 
the most common triggers of ACLF.7 Result of the 
aforementioned study was in accordance with the data 
of ACLF aetiologies in Fatmawati General Hospital 
where most cases were caused by hepatitis B. 
Dysfunction up to multiple organ failure is the main 
manifestation in ACLF patient. Central nerves, kidney, 
and cardiovascular system are the most common organs 
involved in severe ACLF and are associated with high 
mortality rate.
Hepatic encephalopathy (HE) is one of the 
most common manifestations of ACLF. Research 
data has shown that hepatic encephalopathy may 
emerge in 40% patients.8 Study has also shown that 
hepatic encephalopathy is associated with higher 
mortality rate, particularly grade 3 and 4 hepatic 
encephalopathy.8 In this study which was performed 
in Fatmawati General Hospital, 90% patients suffered 
from HE. HE may occur either upon admission or 
emerge during hospitalization. HE may happen due to 
local or systemic disorder. Patients with HE showed 
increase of ammonia due to functional disturbance of 
the blood brain barrier. The increase of brain ammonia 
level and cerebral haemodynamic disturbance is known 
as the main aetiological factor. These changes include 
disorder in neurotransmission which is, disorder in the 
ergonom aminobutyric acid (GABA) system, energy 
GLVWXUEDQFHZKLFKLVGHFUHDVHRIFHUHEUDOEORRGÀRZ
inhibition of cerebral energy metabolism by ammonia), 
brain oedema (which is elevated ammonia level, 
K\SRQDWUHPLDDQGQHXURLQÀDPPDWLRQQLWUDWHR[LGH
generation, prostanoid, astrocytic oedema).9 
HE in ACLF setting has a different pathway from 
cirrhosis patient with acute decompensation without 
ACLF. Patient with HE related ACLF suffered due 
WRWKHJHQHUDOLQÀDPPDWLRQUHDFWLRQZKLFKPD\SOD\
role in brain and other organ dysfunction. This causes 
very bad survival rate. In addition to direct cause from 
liver dysfunction, HE in ACLF is often correlated 
with the presence of bacterial infection, alcoholism, 
or hyponatremia.9 Isolated HE usually occur due to 
the long-term use of diuretic, exaggerated protein 
consumption, and is not correlated with decreased liver 
IXQFWLRQ$EVHQFHRIVLJQL¿FDQWLQÀDPPDWLRQUHDFWLRQ
and the low prevalence of organ failure causes HE in 
cirrhosis without ACLF has better prognosis.
Beside consciousness disorder in the form of 
hepatic encephalopathy, ACLF patients in Fatmawati 
General Hospital also suffered from acute kidney 
disorder in various degree in 90% patients. Kidney 
IDLOXUHLVGH¿QHGE\&/,)62)$DVFUHDWLQLQH!JUG/
and the need of renal replacement therapy. From nine 
patients whose blood creatinine were elevated, six of 
WKHPFRXOGEHFODVVL¿HGWRNLGQH\IDLOXUHDFFRUGLQJWR
CLIF SOFA criteria. Renal dysfunction was observed 
in 22.8-34% ACLF patients and 51% if using acute 
kidney injury network (AKIN) criteria.8 
In the study, it is known that kidney failure is 
the most common organ failure in ACLF (55.8%), 
followed by liver, cerebral/brain, and haematology/
coagulation failure (43.6%, 27.7%, and 24.1%). In the 
reality, kidney disturbance is an important thing and 
often happens in ACLF and carries a bad prognosis. 
Higher mortality rate is found in ACLF patients with 
single organ failure of the kidney compared to patients 
with other single organ failure. In the above case series, 
LQ SDWLHQWVZKR IXO¿OOHG WKH FULWHULD RI UHQDO IDLOXUH
according to CLIF SOFA, in average, they can survive 
up to 3 days after hospital admission compared to the 
group without renal failure who could survive longer 
up to 6.25 days.
Figure 1. Correlation between kidney disorder and mortality 
in ACLF
days of treatment
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In a study involving 562 hospitalized cirrhosis 
patients showed that the most common causes of renal 
failure in ACLF patients include bacterial infection 
(46%), hypovolemia (32%), hepato renal syndrome/ 
HRS (13%) and intrinsic renal failure (9%).9
Another organ system dysfunction frequently happen 
in ACLF patients is cardiovascular disturbance. Six 
from 10 patients who fell into the inclusion criteria 
need blood pressure support during the hospitalization. 
In ACLF patient, decreased systemic resistance, 
decreased mean arterial pressure, and increased hepatic 
vein pressure gradient may occur. This can happen 
as a result of circulating pro-inflammatory cytokines, 
such as tumor necrosis factor (TNF) alpha causing 
peripheral vasodilation and the worsening of intrahepatic 
resistance. This eventually may result in the decreased 
blood pressure which require blood pressure supporting 
agent. Decreasing blood pressure may also be caused 
by the relative insufficiency of adrenal until the serum 
cortisol level becomes low and finally causes the 
decreased peripheral response towards vasoconstrictor.9
Beside the difficult diagnosis and the frequency 
of delay, ACLF has a high mortality as a result of 
the absence of specific management. Currently, the 
treatment given is an effort to improve organ failure 
and decrease further complications. In the patient, 
infection needs to be considered because it could be 
the triggering factor; Thus, early identification and 
infection management with antibiotic administration 
becomes important. The most common predisposing 
and aetiology factor of ACLF is the presence of 
Hepatitis B infection. Management of hepatitis B 
patient with antiviral may show improvement if it is 
administered in the right time. Several studies have 
shown that the decrease of HBV-DNA > 2 logs in 
2-week time may improve survival. This is associated 
with the suppression of hepatocellular necrosis and 
cytokine release. Nucleotide analogue needs to be 
given early in all HBV infected patients while waiting 
for HBV DNA level confirmation. Medicine which can 
be used include tenofovir, entecavir, or telbivudin.8
Currently, there are several alternatives beside liver 
transplant in ACLF management. Granulocyte colony-
stimulating factor (GCSF) may help regeneration 
and mobilisation of CD34+ cell from bone marrow. 
Significantly, this therapy can increase survival rate 
and clinical improvement in ACLF related hepatitis B. 
GCSF administration may improve renal disturbance 
and hyponatremia.10 However, more data is needed 
to recommend the routine use of this therapy. 
Additionally, there is an option of liver dialysis. Liver 
dialysis is known to improve bilirubin level, hepatic 
encephalopathy, and hepatorenal syndrome, but not 
affecting the 28 days survival or mortality.11 
Patients with ACLF is better hospitalized in ICU or 
hospital which has a transplant centre. Organ function 
needs to be monitored closely and early management 
is given towards particular organ to prevent multiple 
organ failure. Liver transplantation is a definitive 
therapy in all ACLF patients. All patients needs to 
be evaluated for liver transplant consideration in the 
absence of contraindication. In grade II and III ACLF 
patients, survival rate without liver transplant is 
< 20%, but increases to 80% in patients who receive 
liver transplant.3
Figure 2. Survival comparison of grade 2 and 3 ACLF patients
ACLF is a dynamic proses which may improve or 
get worsened. It is known that the final clinical outcome 
can be assessed in the day-7 after diagnosis has been 
confirmed. ACLF can improve in 55% patients with 
grade 1 ACLF, and only 15% in patients with grade III 
ACLF.1 In this study, all ACLF patients passed away 
and all patients with grade 3 ACLF passed away within 
7 days of hospitalization.
CONCLUSION
ACLF is a new entity which still has no single 
definition that has been accepted universally. In 
addition, the main pathophysiology of ACLF is 
still controversial, although triggering factors such 
as infection and systemic inflammation has been 
estimated to be the main cause. ACLF prognosis is 
associated with the number of organ being involved 
and according to EASL criteria, the severity degree 
can be calculated using the chronic liver failure organ 
failure (CLIF-ACLF) score. This score determines the 
degree of severity and can be used to estimate short-
term mortality rate quite well. 
days of treatment
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The management of ACLF is focused on the 
management and prevention of further extrahepatic 
organ failure. Liver transplantation is considered 
in several patients. Prevention of ACLF plays an 
important role because ACLF is still an entity which 
is considered new, and not all clinicians can identify 
this syndrome and its implications. Primary prevention 
can be done particularly in patients with chronic 
hepatitis infection. In ACLF case with one organ 
failure, secondary prevention can be done in the form 
of preventing the involvement of other organs with 
aggressive medical management.
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